Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference
October 05 2020 - 4:05PM
Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical
company focused on developing next-generation viral immunotherapies
to transform outcomes for cancer patients, today announced that its
President and Chief Executive Officer, Theodore (Ted) A. Ashburn,
M.D., Ph.D., will present a company overview at the Chardan 4th
Annual Genetic Medicines Conference, to be held virtually on
Tuesday, October 6, 2020 at 4:15 p.m. ET.
About
OncorusOncorus is a clinical stage biopharmaceutical
company focused on developing next-generation viral immunotherapies
to transform outcomes for cancer patients. Using its two distinct
proprietary platforms, the Company is developing a pipeline of
intratumorally and intravenously administered product candidates
designed to selectively attack and kill tumor cells and stimulate
multiple arms of the immune system against tumors. Oncorus’ lead
product candidate, ONCR-177, is an intratumorally administered
viral immunotherapy based on its oncolytic HSV-1 platform, referred
to as the oHSV Platform, which leverages the Herpes Simplex Virus
type 1, or HSV-1, a virus which has been clinically proven to
effectively treat certain cancers. For more information, please
visit www.oncorus.com.
Investors:John McCabeir@oncorus.com
Media:Liz Melonemedia@oncorus.com
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jul 2023 to Jul 2024